Rezolute to Participate in Upcoming Investor Conferences
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, has announced its participation in two upcoming investor conferences. The company will attend Guggenheim's Inaugural Healthcare Innovation Conference from November 11-13, 2024, and the Jefferies London Healthcare Conference from November 19-21, 2024.
Management will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through their Guggenheim and Jefferies representatives.
Rezolute (Nasdaq: RZLT), una società biofarmaceutica nella fase avanzata, focalizzata sullo sviluppo di terapie trasformative per malattie rare, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda sarà presente alla Conferenza Inaugurale sull'Innovazione Sanitaria di Guggenheim dal 11 al 13 novembre 2024, e alla Conferenza Sanitaria di Jefferies a Londra dal 19 al 21 novembre 2024.
La direzione sarà disponibile per incontri individuali con gli investitori durante entrambe le conferenze. Gli investitori interessati possono programmare incontri tramite i loro rappresentanti di Guggenheim e Jefferies.
Rezolute (Nasdaq: RZLT), una compañía biofarmacéutica en etapa avanzada que se centra en el desarrollo de terapias transformadoras para enfermedades raras, ha anunciado su participación en dos próximas conferencias para inversores. La compañía asistirá a la Conferencia Inaugural de Innovación en Salud de Guggenheim del 11 al 13 de noviembre de 2024, y a la Conferencia de Salud de Jefferies en Londres del 19 al 21 de noviembre de 2024.
La dirección estará disponible para reuniones uno a uno con los inversores durante ambas conferencias. Los inversores interesados pueden programar reuniones a través de sus representantes de Guggenheim y Jefferies.
레졸루트 (Nasdaq: RZLT)는 희귀 질환을 위한 혁신적인 치료제를 개발하는 데 주력하는 후기 단계의 생물 제약 회사로, 두 개의 다가오는 투자자 회의에 참석할 예정이라고 발표했습니다. 이 회사는 2024년 11월 11일부터 13일까지 열리는 구겐하임 최초의 헬스케어 혁신 컨퍼런스와 2024년 11월 19일부터 21일까지 개최되는 제퍼리스 런던 헬스케어 컨퍼런스에 참석합니다.
동안 양 회의에서 경영진이 투자자와의 개별 미팅을 위해 대기합니다. 관심 있는 투자자는 구겐하임 및 제퍼리스 대표를 통해 미팅을 예약할 수 있습니다.
Rezolute (Nasdaq: RZLT), une entreprise biopharmaceutique en phase avancée axée sur le développement de thérapies transformatrices pour les maladies rares, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise assistera à la Conférence Inaugurale sur l'Innovation en Santé de Guggenheim du 11 au 13 novembre 2024, ainsi qu'à la Conférence sur la Santé de Jefferies à Londres du 19 au 21 novembre 2024.
La direction sera disponible pour des réunions individuelles avec les investisseurs lors des deux conférences. Les investisseurs intéressés peuvent programmer des réunions par l'intermédiaire de leurs représentants Guggenheim et Jefferies.
Rezolute (Nasdaq: RZLT), ein Biopharma-Unternehmen in der späten Phase, das sich auf die Entwicklung von transformierenden Therapien für seltene Krankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an der Guggenheim Inaugural Healthcare Innovation Conference vom 11. bis 13. November 2024 und an der Jefferies London Healthcare Conference vom 19. bis 21. November 2024 teilnehmen.
Das Management wird während beider Konferenzen für Einzelgespräche mit Investoren zur Verfügung stehen. Interessierte Investoren können Meetings über ihre Vertreter von Guggenheim und Jefferies vereinbaren.
- None.
- None.
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that management will participate in the following investor conferences:
Event: Guggenheim’s Innaugural Healthcare Innovation Conference
Date: November 11-13, 2024
Event: Jefferies London Healthcare Conference
Date: November 19-21, 2024
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
FAQ
Which investor conferences will Rezolute (RZLT) attend in November 2024?
How can investors meet with Rezolute (RZLT) management at the November 2024 conferences?
What is Rezolute's (RZLT) business focus according to the November 2024 announcement?
